[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 37 of about 37
3. Longatto-Filho A, Pinheiro C, Martinho O, Moreira MA, Ribeiro LF, Queiroz GS, Schmitt FC, Baltazar F, Reis RM: Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma. BMC Cancer; 2009 Jun 29;9:212
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma.
  • BACKGROUND: Adenosquamous carcinoma of the uterine cervix is an infrequent but aggressive subtype of cervical cancer.
  • The objective of this study was to investigate EGFR, PDGFRA and VEGFR2 RTKs overexpression and activating gene mutations in a cohort of 30 adenosquamous carcinomas of the uterine cervix.
  • CONCLUSION: This is the most extensive analysis of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinomas.
  • Despite the absence of EGFR and PDGFRA activating mutations, the presence of overexpression of these three important therapeutic targets in a subset of cases may be important in predicting the sensitivity of adenosquamous carcinoma to specific anti-RTKs drugs.
  • [MeSH-major] Carcinoma / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Receptor, Epidermal Growth Factor / genetics. Receptor, Platelet-Derived Growth Factor alpha / genetics. Uterine Cervical Neoplasms / genetics. Vascular Endothelial Growth Factor Receptor-2 / genetics

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] PLoS Med. 2008 Jan 29;5(1):e19 [18232728.001]
  • [Cites] Curr Opin Investig Drugs. 2008 Dec;9(12):1324-35 [19037839.001]
  • [Cites] Nature. 2001 May 17;411(6835):355-65 [11357143.001]
  • [Cites] Cancer. 2003 May 1;97(9):2196-202 [12712471.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):414-9 [12798704.001]
  • [Cites] Histopathology. 2003 Jul;43(1):33-9 [12823710.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2985-91 [12912946.001]
  • [Cites] Gynecol Oncol. 2003 Nov;91(2):346-53 [14599865.001]
  • [Cites] Gynecol Oncol. 2003 Dec;91(3):558-62 [14675676.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1366-74 [14977838.001]
  • [Cites] J Pathol. 2004 Mar;202(3):313-20 [14991896.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Biochemistry. 1987 Mar 10;26(5):1443-51 [3494473.001]
  • [Cites] J Clin Pathol. 1993 Feb;46(2):149-53 [8459036.001]
  • [Cites] J Virol. 1993 Aug;67(8):4521-32 [8392596.001]
  • [Cites] Cancer. 1996 Aug 1;78(3):433-40 [8697388.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):577-86 [10100709.001]
  • [Cites] Cell Mol Life Sci. 2004 Dec;61(23):2924-31 [15583854.001]
  • [Cites] Acta Neuropathol. 2005 Feb;109(2):207-10 [15791479.001]
  • [Cites] Oncogene. 2005 Apr 7;24(15):2585-8 [15735736.001]
  • [Cites] Breast Cancer Res. 2005;7(5):R788-95 [16168125.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):303-15 [16507827.001]
  • [Cites] Mod Pathol. 2006 May;19(5):701-7 [16557278.001]
  • [Cites] Clin Transl Oncol. 2006 Feb;8(2):77-82 [16632420.001]
  • [Cites] Int J Cancer. 2006 Jul 1;119(1):91-8 [16450401.001]
  • [Cites] Semin Oncol. 2006 Aug;33(4):407-20 [16890796.001]
  • [Cites] J Pathol. 2006 Aug;209(4):445-53 [16739104.001]
  • [Cites] Int J Gynecol Pathol. 2007 Jul;26(3):235-41 [17581404.001]
  • [Cites] Drugs. 2007;67(14):2045-75 [17883287.001]
  • [Cites] Oncol Rep. 2007 Nov;18(5):1201-6 [17914573.001]
  • [Cites] Curr Med Chem. 2007;14(23):2495-516 [17979703.001]
  • [Cites] Oncol Rep. 2008 Jan;19(1):65-71 [18097577.001]
  • [Cites] Gynecol Oncol. 2008 Jan;108(1):42-6 [17980406.001]
  • [Cites] Gynecol Oncol. 2008 Jan;108(1):182-90 [18028988.001]
  • [Cites] J Clin Pathol. 2008 Feb;61(2):203-8 [17827398.001]
  • [Cites] PLoS One. 2008;3(2):e1652 [18286204.001]
  • [Cites] Gynakol Geburtshilfliche Rundsch. 2008;48(2):94-100 [18431049.001]
  • [Cites] J Gastroenterol. 2008;43(7):499-508 [18648736.001]
  • [Cites] Int J Gynecol Cancer. 2008 Jul-Aug;18(4):749-54 [17949425.001]
  • [Cites] BMC Cancer. 2008;8:232 [18700025.001]
  • [Cites] Gynecol Oncol. 2008 Sep;110(3 Suppl 2):S72-6 [18544460.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 2008 Sep;30(7):543-88 [18985183.001]
  • [Cites] Gynecol Oncol. 2008 Nov;111(2):350-5 [18708242.001]
  • [Cites] Drugs. 2000;60 Suppl 1:15-23; discussion 41-2 [11129168.001]
  • (PMID = 19563658.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  • [Other-IDs] NLM/ PMC2711112
  •  go-up   go-down


Advertisement
4. Sasieni P, Castanon A, Cuzick J: Screening and adenocarcinoma of the cervix. Int J Cancer; 2009 Aug 1;125(3):525-9
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening and adenocarcinoma of the cervix.
  • Screening has had a major impact on cervical cancer in many countries.
  • Although there can be no doubt about its effectiveness in preventing squamous-cell carcinoma, there is little evidence of any benefit on adenocarcinoma and adenosquamous carcinoma of the cervix, and many authors have concluded that it is ineffective.
  • Among 3,305 cases with known histology, 641 had adenocarcinoma and 133 adenosquamous carcinoma.
  • The risk reduction associated with 3-yearly screening was greater for squamous carcinoma (75%, 95%CI 71-79%) and adenosquamous carcinoma (83%, 95%CI 68-91%) than for adenocarcinoma (43%, 95%CI 24-58%).
  • Among stage 1B+ cases, 83% (335/406) of women with adenocarcinoma had been screened within 10 years of diagnosis.
  • This is very similar to controls (82%, 3,292/3,965), but much higher than in women with squamous carcinoma (57%, 852/1,493).
  • Incidence of adenocarcinoma was low within 2.5 years of a negative smear (OR 2.3, 95%CI 0.15-0.34), but was no different from the background rates 4.5-5.5 years after a negative smear.
  • We conclude that screening has reduced the incidence of adenocarcinoma of the cervix, but the prognostic value of cytology is less (in both magnitude and duration) for adenocarcinoma than for squamous carcinoma.
  • The impact of screening on adenosquamous carcinoma is similar to its impact on squamous carcinoma.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / prevention & control. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Adenosquamous / prevention & control. Mass Screening. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / prevention & control
  • [MeSH-minor] Adult. Aged. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / prevention & control. Case-Control Studies. Colposcopy. Female. Great Britain / epidemiology. Humans. Incidence. Logistic Models. Middle Aged. Neoplasm Invasiveness


5. Hope AJ, Saha P, Grigsby PW: FDG-PET in carcinoma of the uterine cervix with endometrial extension. Cancer; 2006 Jan 1;106(1):196-200
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET in carcinoma of the uterine cervix with endometrial extension.
  • BACKGROUND: The authors wished to determine whether pretreatment pathologic evidence of endometrial invasion correlated with fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) findings and outcomes in patients with carcinoma of the uterine cervix.
  • METHODS: Pretreatment whole body FDG-PET was performed in 58 patients with cervical carcinoma who also underwent pathologic evaluation of the endometrium by biopsy or dilation and curettage.
  • CONCLUSIONS: Endometrial extension in cervical cancer correlated strongly with risk of FDG-PET detected lymph node metastases in this study's population and was associated with a poor prognosis.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Carcinoma, Neuroendocrine / radionuclide imaging. Carcinoma, Squamous Cell / radionuclide imaging. Endometrial Neoplasms / radionuclide imaging. Uterine Cervical Neoplasms / radionuclide imaging
  • [MeSH-minor] Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / radionuclide imaging. Carcinoma, Adenosquamous / secondary. Carcinoma, Adenosquamous / therapy. Cervix Uteri / pathology. Cervix Uteri / radionuclide imaging. Combined Modality Therapy. Disease-Free Survival. Female. Fluorodeoxyglucose F18. Humans. Lymphatic Metastasis. Neoplasm Invasiveness. Positron-Emission Tomography. Prospective Studies. Radiopharmaceuticals. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16302228.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


6. Yan M, Zhang YN, He JH, Huang H: [Prognosis analysis of 83 cases of cervical adenosquamous carcinoma]. Ai Zheng; 2008 Sep;27(9):956-61
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognosis analysis of 83 cases of cervical adenosquamous carcinoma].
  • BACKGROUND & OBJECTIVE: Cervical adenosquamous carcinoma is a special histological type of cervical carcinoma.
  • This study was to explore the clinic-pathologic characteristics and prognostic factors of cervical adenosquamous carcinoma.
  • METHODS: Clinical data of 83 pathologically confirmed adenosquamous cervical carcinoma patients in Sun Yat-sen University Cancer Center from Nov.
  • CONCLUSIONS: Lymph node metastasis is an independent risk factor for prognosis in cervical adenosquamous carcinoma.
  • [MeSH-major] Carcinoma, Adenosquamous / therapy. Hysterectomy / methods. Uterine Cervical Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18799035.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 56H9L80NIZ / Peplomycin; 74KXF8I502 / Aclarubicin; Q20Q21Q62J / Cisplatin; CAP therapy protocol
  •  go-up   go-down


7. Cai HN, Wu XF, Xiang QY, Xiong YY, Zeng J: [Clinical analysis of 21 cases of cervical adenosquamous carcinoma]. Zhonghua Fu Chan Ke Za Zhi; 2008 Feb;43(2):124-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 21 cases of cervical adenosquamous carcinoma].
  • OBJECTIVE: To study the clinical characteristics, treatment modalities and prognosis of cervical adenosquamous carcinoma.
  • METHODS: The data of 21 patients with adenosquamous cervical cancer who were admitted into Zhongnan Hospital, Wuhan University from Jan 2001 to Dec 2005 were analyzed retrospectively.
  • CONCLUSIONS: Combined therapy should be given to patients with adenosquamous carcinoma of the cervix.
  • Surgical therapy and chemotherapy play an important role in the management and prognosis of adenoquamous carcinoma of cervix.
  • Preserve of ovary for patients with adenosquamous carcinoma of the cervix should only be done when the ovary is confirmed free from any malignant involvement by pathology.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / therapy. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / therapy


8. Amălinei C, Balan R, Stolnicu S, Rădulescu D, Boeru C, Cotuţiu C: Adenosquamous cervical carcinoma morphological characteristics. Rev Med Chir Soc Med Nat Iasi; 2005 Apr-Jun;109(2):343-6
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous cervical carcinoma morphological characteristics.
  • Adenosquamous carcinomas range between 5-25% of cervical cancers and are composed by an admixture of malignant squamous and glandular elements.
  • Differential diagnosis with endometrioid adenocarcinoma of the cervix with squamous metaplasia was made.
  • Four cases (26.66%) were subtyped as clear cell adenosquamous carcinomas and 2 cases (13.33%) were subtyped as glassy cell carcinomas, exhibiting finely granular ground glass type cytoplasm.
  • One case presented extension to the uterine body.
  • One case, diagnosed as glassy cell subtype, presented regional lymph node metastases.
  • Our study concluded the occurrence of adenosquamous cervical carcinomas at a similar age with squamous cervical carcinomas in the investigated group of patients.
  • As adenosquamous cervical carcinomas are considered expressions of a biphasic differentiation of a single pluripotential sub-columnar reserve cell, a similar degree of differentiation of the two components would be expected.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607797.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


9. Yoshida T, Sano T, Oyama T, Kanuma T, Fukuda T: Prevalence, viral load, and physical status of HPV 16 and 18 in cervical adenosquamous carcinoma. Virchows Arch; 2009 Sep;455(3):253-9
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence, viral load, and physical status of HPV 16 and 18 in cervical adenosquamous carcinoma.
  • Adenosquamous carcinoma of the uterine cervix is a rare mixture of malignant squamous and glandular epithelial elements and accounts for approximately 10% of cervical carcinomas.
  • The aims of the present study were to evaluate the prevalence, physical status, and viral load of HPV 16 and 18 in adenosquamous carcinoma.
  • Formalin-fixed paraffin-embedded tissue samples from 20 cases of histologically diagnosed adenosquamous carcinoma were examined.
  • The mean HPV 16 DNA copy numbers/cell was 7.22 in the squamous elements and 1.33 in the glandular elements (p=0.04) while the corresponding mean HPV 18 DNA copy numbers/cell was 1.50 and 0.89, respectively.
  • The prevalence of HPV 18 in adenosquamous carcinoma was high and many HPV 18-positive cases were the pure integrated form resulting in very low copy numbers/cell.
  • [MeSH-major] Carcinoma, Adenosquamous / virology. Human papillomavirus 16 / isolation & purification. Human papillomavirus 18 / isolation & purification. Uterine Cervical Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19727809.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


10. Ueda Y, Miyatake T, Okazawa M, Kimura T, Miyake T, Fujiwara K, Yoshino K, Nakashima R, Fujita M, Enomoto T: Clonality and HPV infection analysis of concurrent glandular and squamous lesions and adenosquamous carcinomas of the uterine cervix. Am J Clin Pathol; 2008 Sep;130(3):389-400
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonality and HPV infection analysis of concurrent glandular and squamous lesions and adenosquamous carcinomas of the uterine cervix.
  • We analyzed the clonality and human papillomavirus (HPV) infection status of concurrent glandular and squamous lesions and adenosquamous carcinomas of the uterine cervix to clarify their histogenesis.
  • HPV was in a mixed integrated-episomal form in a monoclonal GD, an adenocarcinoma in situ, and an adenocarcinoma.
  • Both tumor components were monoclonal in origin in 6 adenosquamous carcinomas, with identical patterns of X-chromosomal inactivation and types and physical status of HPV.
  • These results imply that the concurrent glandular and squamous lesions are formed separately, whereas adenosquamous carcinoma is more likely to be a combination tumor of monoclonal origin, and that integration of HPV has an important role in the progression from polyclonal GD through monoclonal expansion to adenocarcinoma in situ and adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / virology. Carcinoma, Adenosquamous / virology. Carcinoma, Squamous Cell / virology. Cervix Uteri / pathology. Cervix Uteri / virology. Endometrial Neoplasms / virology. Papillomavirus Infections / pathology
  • [MeSH-minor] Antibodies, Viral / analysis. Cervical Intraepithelial Neoplasia / immunology. Cervical Intraepithelial Neoplasia / pathology. Female. Human papillomavirus 16 / isolation & purification. Human papillomavirus 18 / isolation & purification. Humans. Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18701412.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral
  •  go-up   go-down


11. Neumann G, Rasmussen KL, Petersen LK: Cervical adenosquamous carcinoma: tumor implantation in an episiotomy scar. Obstet Gynecol; 2007 Aug;110(2 Pt 2):467-9
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical adenosquamous carcinoma: tumor implantation in an episiotomy scar.
  • BACKGROUND: We report a rare case of a cervical adenosquamous carcinoma, initially diagnosed during delivery, with subsequent implantation in the episiotomy scar 5 weeks postpartum.
  • CASE: A 35-year-old woman with cervical adenosquamous carcinoma diagnosed during delivery was treated with radical abdominal hysterectomy with bilateral pelvic lymphadenectomy.
  • CONCLUSION: This case illustrates the importance of inspection of the perineal area during delivery in patients diagnosed with cervical cancer.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Cicatrix / pathology. Episiotomy. Pregnancy Complications, Neoplastic / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Combined Modality Therapy. Fatal Outcome. Female. Humans. Hysterectomy. Lymph Node Excision. Lymphatic Metastasis / pathology. Neoplasm Recurrence, Local. Pregnancy. Puerperal Disorders / diagnosis. Puerperal Disorders / pathology. Puerperal Disorders / therapy


12. Tong SY, Lee YS, Park JS, Namkoong SE: Human papillomavirus genotype as a prognostic factor in carcinoma of the uterine cervix. Int J Gynecol Cancer; 2007 Nov-Dec;17(6):1307-13
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus genotype as a prognostic factor in carcinoma of the uterine cervix.
  • The clinical implications of specific human papillomavirus (HPV) types in invasive cervical carcinomas are only now beginning to be appreciated.
  • The objective of this study was to determine the clinical implications and prognostic value of the HPV genotype in cervical carcinomas.
  • In this study, we employed an HPV DNA chip to detect the type-specific sequence of HPV from cervical swabs taken from women with biopsy-proven neoplastic lesions of the cervix.
  • The HPV-16-related types were detected more frequently in patients with squamous cell carcinomas, whereas the HPV-18-related types were more prevalent in cases of adenocarcinomas and adenosquamous carcinomas (P < 0.05).
  • We conclude that neither the presence nor type of HPV DNA bears any prognostic significance in cases of cervical carcinoma.
  • [MeSH-major] Carcinoma / virology. Papillomaviridae / genetics. Papillomavirus Infections / complications. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Adult. Aged. Cervix Uteri / pathology. Female. Genotype. Humans. Middle Aged. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17425678.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Bao YP, Li N, Smith JS, Qiao YL: Human papillomavirus type-distribution in the cervix of Chinese women: a meta-analysis. Int J STD AIDS; 2008 Feb;19(2):106-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus type-distribution in the cervix of Chinese women: a meta-analysis.
  • The aim of the study was to determine human papillomavirus (HPV) type-distribution in the cervix of Chinese women, and to estimate the potential future impact of HPV prophylactic vaccines for cervical cancer prevention in China.
  • A total of 32 studies using polymerase chain reaction for HPV detection were included in the meta-analysis, including 2844 invasive cervical cancer (ICC), 820 high-grade squamous intraepithelial lesions (HSIL), 432 low-grade squamous intraepithelial lesions (LSIL) and 2902 women with normal cytology/histology.
  • The overall and type-specific HPV prevalence of 18 HPV types (HPV 6, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 70, 73 and 82 of different cervical stages) were estimated.
  • HPV 16 was the predominant type in all cervical stages.
  • [MeSH-major] Cervix Uteri / virology. Papillomaviridae / classification. Papillomaviridae / isolation & purification. Papillomavirus Infections / epidemiology. Uterine Cervical Diseases / virology. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / prevention & control. Adenocarcinoma / virology. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Adenosquamous / prevention & control. Carcinoma, Adenosquamous / virology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / prevention & control. Carcinoma, Squamous Cell / virology. China / epidemiology. DNA, Viral / genetics. Female. Humans. Papillomavirus Vaccines / immunology


14. Bolanca IK, Ciglar S: Evaluation of p16INK4a in cervical lesion of premenopausal and postmenopausal women. Coll Antropol; 2007 Apr;31 Suppl 2:107-11
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of p16INK4a in cervical lesion of premenopausal and postmenopausal women.
  • A total of 137 cervical specimens were enrolled in this study, of which 77 and 60 cervical smears were taken from premenopausal and postmenopausal women, respectively.
  • Two cervical smears were taken simultaneously in 68 women, one for conventional cytology and the other for immunostaining.
  • Additional 69 cervical smears were taken from the archive, decolorized and then used for immunostaining.
  • In premenopausal women 1 out of 14 (7.1%) with negative cytology, 7 out of 24 (29.2%) with low grade squamous intra-epithelial lesion (LSIL), all 35 (100%) with high grade squamous intraepithelial lesion (HSIL) and all 4 (100%) with squamous cell carcinoma (confirmed by histopathology) had positive staining to p16INK4a.
  • In postmenopausal women p16INK4a positivity was observed in 4 out of 7 (57.1%) cases of LSIL, 12 out of 14 (85.7%) cases of HSIL and all 4 out of 5 (80%) different cases of carcinoma (1 cervical adenosquamous carcinoma and 3 cervical squamous cell carcinoma in situ confirmed by histopathology), but none of 34 smears with normal cytology.
  • In the group of postmenopausal women, 16 out of 60 (26.7%) cases the cytological diagnosis was established on the basis of pl6lNK4a immunostaining as being HSIL.
  • From our preliminary study on a limited number of samples, we can however conclude that pl6INK4a immunostaining is a very useful tool for cytological diagnosis enabling to distinguish HSIL from normal, reactive or inflammatory changes.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16. Papanicolaou Test. Postmenopause. Premenopause. Uterine Cervical Neoplasms / diagnosis. Vaginal Smears / classification


15. Cortés-Charry R, Figueira LM, Nieves L, Colmenter L: Metastasis detection with 18 FDG-positron emission tomography/computed tomography in gestational trophoblastic neoplasia: a report of 2 cases. J Reprod Med; 2006 Nov;51(11):897-901

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The imaging methods proposed by the International Consensus for the Diagnosis of Metastases in Trophoblastic Neoplasia are sufficient to stage the disease in most cases.
  • A 51-year-old woman was referred to the Hospital Universitario de Caracas from another hospital with a diagnosis of cervical adenosquamous carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17165437.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


16. Rodríguez-Sastre MA, González-Maya L, Delgado R, Lizano M, Tsubaki G, Mohar A, García-Carrancá A: Abnormal distribution of E-cadherin and beta-catenin in different histologic types of cancer of the uterine cervix. Gynecol Oncol; 2005 May;97(2):330-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormal distribution of E-cadherin and beta-catenin in different histologic types of cancer of the uterine cervix.
  • OBJECTIVE: The goal of this study was to analyze the cellular distribution and possible alterations of beta-catenin and E-cadherin proteins in different histologic types of uterine cervical cancer and precursor lesions, compared to normal controls.
  • METHODS: We performed an immunochemical staining analysis of the cellular distribution of beta-catenin and E-cadherin proteins in biopsy samples from 20 normal exocervical squamous epithelium, 43 premalignant lesions, and a large series of 126 invasive tumors of different histologic types that included 68 squamous carcinomas, 31 adenosquamous carcinomas, and 27 adenocarcinomas.
  • Similarly, we found that E-cadherin exhibit a significant abnormal distribution in the cytoplasm of 58% of premalignant lesions (P < 0.05) and in more than 71% of squamous carcinoma and adenosquamous carcinoma when compared with normal tissue (P < 0.05).
  • CONCLUSION: Our findings indicate that cellular alterations of both beta-catenin and E-cadherin are frequent in tumors of the uterine cervix of different histologic types, and support a role for these proteins in cervical cancer development.
  • [MeSH-major] Cadherins / metabolism. Cytoskeletal Proteins / metabolism. Trans-Activators / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cervix Uteri / metabolism. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. beta Catenin

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863126.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cadherins; 0 / Cytoskeletal Proteins; 0 / Trans-Activators; 0 / beta Catenin
  •  go-up   go-down


17. Zannoni GF, Vellone VG, Carbone A: Morphological effects of radiochemotherapy on cervical carcinoma: a morphological study of 50 cases of hysterectomy specimens after neoadjuvant treatment. Int J Gynecol Pathol; 2008 Apr;27(2):274-81
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphological effects of radiochemotherapy on cervical carcinoma: a morphological study of 50 cases of hysterectomy specimens after neoadjuvant treatment.
  • The introduction of radiochemotherapy for treatment of advanced cervical cancers represents a new chapter in surgical pathology.
  • The study group included 50 women with a histological diagnosis of advanced cervical carcinoma (43 squamous, 3 adenosquamous, 2 adenocarcinoma, 1 glassy cell, and 1 undifferentiated; International Federation of Gynecology and Obstetrics stage Ib-III) receiving a platinum-based chemotherapy concomitant with external beam radiotherapy before radical surgery.
  • In some cases, multinucleated neoplastic giant cell coexisted with reactive foreign body-like giant cells.
  • In most cases, morphological criteria are sufficient to make a diagnosis, but sometimes, the use of immunohistochemistry (keratins and CD68) is a mandatory method to reveal the nature of the lesion.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / pathology. Hysterectomy. Neoadjuvant Therapy / methods. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Biomarkers, Tumor / metabolism. Cervix Uteri / drug effects. Cervix Uteri / radiation effects. Cervix Uteri / surgery. Combined Modality Therapy. Female. Humans. Keratins / metabolism. Middle Aged

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18317212.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Biomarkers, Tumor; 0 / CD68 antigen, human; 68238-35-7 / Keratins
  •  go-up   go-down


18. Vrdoljak E, Boraska Jelavic T, Saratlija-Novakovic Z, Hamm W: Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy in the treatment of locally advanced adenocarcinoma or adenosquamous carcinoma of the cervix uteri. Eur J Gynaecol Oncol; 2005;26(6):602-4
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy in the treatment of locally advanced adenocarcinoma or adenosquamous carcinoma of the cervix uteri.
  • The optimal treatment of women with locally advanced adenocarcinoma or adenosquamous carcinoma of the cervix uteri is still undefined.
  • We report a series of four consecutive patients with locally advanced adeno- or adenosquamous carcinomas of the uterine cervix (FIGO Stages IB-IIIB) treated by concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by one to four cycles of consolidation chemotherapy with the same drug combination.
  • Despite the low number of patients in this series we may conclude that concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy with the same drug combination is an efficacious treatment of patients with locally advanced adeno- or adenosquamous carcinomas of the cervix uteri.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Carcinoma, Adenosquamous / drug therapy. Uterine Cervical Neoplasms / drug therapy


19. Ikeda O, Mizukami N, Murata Y, Arakawa A, Katabuchi H, Okamoto H, Yasunaga T, Tsunawaki A, Yamashita Y: Randomized comparison of intra-arterial chemotherapy versus intra-arterial chemotherapy and gelfoam embolization for treatment of advanced cervical carcinoma. Cardiovasc Intervent Radiol; 2005 Nov-Dec;28(6):736-43
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized comparison of intra-arterial chemotherapy versus intra-arterial chemotherapy and gelfoam embolization for treatment of advanced cervical carcinoma.
  • PURPOSE: We evaluated the effects of intra-arterial infusion therapy by comparing the results obtained with a combination of intra-arterial anticancer drugs with and without transcatheter arterial embolization (TAE) in patients with cervical cancer.
  • METHODS: Between April 1999 and March 2003, intra-arterial therapy was administered to 45 patients (mean age 49 years) with cervical cancer.
  • Of these, 18 had stage IIb , 4 had stage IIIa, 19 had stage IIIb, and 4 had stage IVb cancer; the histopathologic types were squamous cell carcinoma (n = 35), adenocarcinoma (n = 8), and adenosquamous carcinoma (n = 2).
  • [MeSH-major] Carcinoma / therapy. Drug Therapy, Combination. Embolization, Therapeutic / methods. Gelatin Sponge, Absorbable / therapeutic use. Hemostatics / therapeutic use. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / adverse effects. Antibiotics, Antineoplastic / therapeutic use. Antimetabolites, Antineoplastic / adverse effects. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Cervix Uteri / pathology. Cisplatin / adverse effects. Cisplatin / therapeutic use. Combined Modality Therapy / adverse effects. Combined Modality Therapy / methods. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Female. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Humans. Infusions, Intra-Arterial / methods. Magnetic Resonance Imaging / methods. Middle Aged. Mitomycin / adverse effects. Mitomycin / therapeutic use. Treatment Outcome


20. Zhao C, Florea A, Austin RM: Clinical utility of adjunctive high-risk human papillomavirus DNA testing in women with Papanicolaou test findings of atypical glandular cells. Arch Pathol Lab Med; 2010 Jan;134(1):103-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Atypical glandular cell (AGC) Papanicolaou (Pap) test interpretations are challenging.
  • Among the 75 cases with hrHPV+ AGC results, 13 (17.3%) had cervical intraepithelial neoplasia grades 2/3, 10 (13.3%) had adenocarcinoma in situ, and 3 (4.0%) had cervical invasive adenocarcinoma, whereas for 234 women with hrHPV(-) results, 1 (0.4%) had cervical intraepithelial neoplasia grades 2/3, 1 (0.4%) had adenocarcinoma in situ, 1 each (0.4%) had cervical adenocarcinoma and ovarian carcinoma, and 8 (3.4%) had endometrial carcinoma.
  • CONCLUSIONS: Positive hrHPV AGC results were most strongly associated with cervical intraepithelial neoplasia grades 2/3 and adenocarcinoma in situ in women younger than 50 years.
  • Positive hrHPV AGC results were also present in all 3 cases of invasive cervical adenocarcinoma in women younger than 50 years.
  • Of note, hrHPV(-) AGC results were present in 10 of 13 carcinomas (76.9%) detected after AGC Pap tests, all in women 40 years or older with endometrial adenocarcinomas (n = 8), ovarian carcinoma (n = 1), and cervical adenosquamous carcinoma in a woman (n = 1) in her 50s.
  • Testing for hrHPV after AGC Pap testing was most helpful in the detection of cervical intraepithelial neoplasia grades 2/3, adenocarcinoma in situ, and invasive cervical adenocarcinomas in women younger than 50 years.
  • [MeSH-major] Adenocarcinoma / pathology. Cervical Intraepithelial Neoplasia / pathology. DNA, Viral. Papanicolaou Test. Papillomaviridae / genetics. Uterine Cervical Neoplasms / pathology. Vaginal Smears
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Carcinoma in Situ / pathology. Carcinoma in Situ / virology. Endometrial Neoplasms / pathology. Endometrial Neoplasms / virology. Female. Humans. Middle Aged. Ovarian Neoplasms / pathology. Ovarian Neoplasms / virology. Retrospective Studies. Risk Factors. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer Screening.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20073612.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


21. Andersson S, Hellström AC, Angström T, Stendahl U, Auer G, Wallin KL: The clinicopathologic significance of laminin-5 gamma2 chain expression in cervical squamous carcinoma and adenocarcinoma. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1065-72
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinicopathologic significance of laminin-5 gamma2 chain expression in cervical squamous carcinoma and adenocarcinoma.
  • Carcinoma of the uterine cervix is one of the most prevalent malignancies among women in developing countries and the third most common type worldwide.
  • Squamous cell carcinoma predominates in the cervix uteri, while adenocarcinoma and adenosquamous carcinomas represent about 10-15% of all cervical cancers.
  • Many studies have confirmed that the human papillomavirus (HPV) is the most important etiologic factor in the development of cervical cancer.
  • The aim of our study was to investigate the expression of the laminin-5 gamma2 chain in primary malignancies of the cervix uteri and to focus on the clinicopathologic significance of the expression of the laminin-5 gamma2 chain in cervical squamous carcinoma and adenocarcinoma with respect to age and survival of the patients.
  • The study consisted of a total of 89 cases of invasive cervical cancer (54 squamous carcinomas and 35 adenocarcinomas).
  • The laminin-5 gamma2 chain was found in 80% of all the squamous carcinoma and in 66% of cervical adenocarcinoma.
  • The univariate analysis in squamous cell carcinoma showed that factors such as the stage of the disease and positive lymph nodes had an impact on the survival of the patients, whereas in the multivariate analysis, only age at diagnosis was an independent prognostic factor.
  • However, in cases with cervical adenocarcinoma, only the stage of the disease was an independent prognostic factor.
  • Our results indicate that the majority of the primary cervical tumors, especially squamous cell carcinoma, showed expression of laminin-5 gamma2 chain immunoreactivity.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Laminin / biosynthesis. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343183.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / LAMC2 protein, human; 0 / Laminin
  •  go-up   go-down


22. Li LJ, Wang ZQ, Wu BP: Peutz-Jeghers syndrome with small intestinal malignancy and cervical carcinoma. World J Gastroenterol; 2008 Dec 28;14(48):7397-9
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peutz-Jeghers syndrome with small intestinal malignancy and cervical carcinoma.
  • Because of small intestinal obstruction, she received the small intestinal polypectomy in 2001, and the pathological diagnosis was Peutz-Jeghers polyp canceration (mucinous adenocarcinoma, infiltrating full-thickness of the intestine).
  • We kept a follow-up study on her and found that she suffered from cervical cancer in 2007, with a pathological diagnosis of cervical adenosquamous carcinoma.The patient presented with typical features of PJS, but without a family history.
  • The PJS accompanied with both small intestinal and cervical malignancies has not been reported so far in the world.
  • [MeSH-major] Adenocarcinoma / complications. Carcinoma, Adenosquamous / complications. Ileal Neoplasms / complications. Peutz-Jeghers Syndrome / complications. Uterine Cervical Neoplasms / complications


23. Lewis H, Yeh LC, Almendral B, Neal H: Monitoring the performance of New Zealand's National Cervical Screening Programme through data linkage. N Z Med J; 2009 Oct 30;122(1305):15-25
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monitoring the performance of New Zealand's National Cervical Screening Programme through data linkage.
  • AIM: To describe the method developed by the National Cervical Screening Programme (NCSP) for review of cases of cervical cancer; present results from the first 4 years of the review and compare these results with those of the earlier New Zealand Cervical Cancer Audit.
  • METHODS: Linkage of cervical cancer registrations from the New Zealand Cancer Registry to smear histories from the NCSP Register via the National Health Index, for the 4-year period 2003-06.
  • RESULTS: A total of 625 women were registered with cervical cancer from 2003-06, of whom 438 were eligible for linkage (women diagnosed with squamous or adenosquamous cervical cancer at <80 years of age).
  • Linkage to screening history revealed that 202 of the 438 eligible women (46%) had never been enrolled in the NCSP; 137 (31%) were enrolled but had only been infrequently or irregularly screened; and 85 (20%) developed cancer despite regular screening (data were missing for 3 women).
  • These results were similar to those found in the New Zealand Cervical Cancer Audit, covering the period 2000-2002.
  • CONCLUSIONS: Ongoing linkage of cancer data to screening data can be used to monitor the performance of the NCSP.
  • Our finding that 80% of potentially preventable cervical cancers involve women who are not enrolled in the Programme or who have been only infrequently and irregularly screened, confirms that improving Programme coverage (currently around 72%) remains a priority.
  • Further investigation (phase 2) is required for the small number of women who develop cervical cancer despite regular screening (average of 21 per year, or approximately 20% of eligible cases), to distinguish interval cancers from possible Programme quality issues.
  • [MeSH-major] Mass Screening / statistics & numerical data. Medical Record Linkage. Quality Assurance, Health Care / methods. Registries / statistics & numerical data. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / prevention & control


24. Takeshima N, Umayahara K, Fujiwara K, Hirai Y, Takizawa K, Hasumi K: Treatment results of adjuvant chemotherapy after radical hysterectomy for intermediate- and high-risk stage IB-IIA cervical cancer. Gynecol Oncol; 2006 Nov;103(2):618-22
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results of adjuvant chemotherapy after radical hysterectomy for intermediate- and high-risk stage IB-IIA cervical cancer.
  • OBJECTIVE: To determine the effectiveness of chemotherapy alone as postoperative adjuvant therapy for intermediate- and high-risk cervical cancer.
  • METHODS: The study group comprised of 65 consecutive patients with stage IB or IIA squamous cell or adenosquamous cervical cancer who were initially treated with radical hysterectomy and pelvic lymphadenectomy between 1993 and 2002.
  • RESULTS: Estimated 5-year disease-free survival was 93.3% for the 30 patients with intermediate-risk tumors (100% for those with squamous cell carcinoma and 71.4% for those with adenosquamous carcinoma) and 85.7% for the 35 patients with high-risk tumors (89.3% for those with squamous cell carcinoma and 71.4% for those with adenosquamous carcinoma).
  • CONCLUSIONS: The treatment results suggest the potential role of adjuvant chemotherapy alone for patients with cervical cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Bleomycin / administration & dosage. Bleomycin / adverse effects. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cisplatin / adverse effects. Disease-Free Survival. Female. Humans. Hysterectomy. Lymph Node Excision. Middle Aged. Mitomycin / administration & dosage. Mitomycin / adverse effects. Neoplasm Staging. Risk Factors. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects


25. Lillo F, Galli L, Lodini S, Taccagni G, Ferrari A, Origoni M: Extralesional detection and load of human papillomavirus DNA: a possible marker of preclinical tumor spread in cervical cancer. J Low Genit Tract Dis; 2008 Jul;12(3):204-9
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extralesional detection and load of human papillomavirus DNA: a possible marker of preclinical tumor spread in cervical cancer.
  • OBJECTIVE: Because the interaction between viral DNA products and cellular regulatory mechanisms is the first step leading to cancerous transformation, the detection of its presence in histologically negative lymph nodes may represent a very early biological step in cancer spread.
  • MATERIALS AND METHODS: Cervical and lymph nodes tissues of 13 cases of invasive cervical cancer were analyzed for human papillomavirus (HPV)-DNA presence and viral load by HPV typing and quantification by real-time polymerase chain reaction.
  • [MeSH-major] Cervix Uteri / virology. DNA, Viral / blood. Lymph Nodes / virology. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / virology. Viral Load
  • [MeSH-minor] Adenocarcinoma / virology. Carcinoma, Adenosquamous / virology. Carcinoma, Squamous Cell / virology. Female. Human papillomavirus 16 / isolation & purification. Humans. Lymphatic Metastasis. Paraffin Embedding. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18596462.001).
  • [ISSN] 1526-0976
  • [Journal-full-title] Journal of lower genital tract disease
  • [ISO-abbreviation] J Low Genit Tract Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


26. Lin Z, Liu M, Li Z, Kim C, Lee E, Kim I: DeltaNp63 protein expression in uterine cervical and endometrial cancers. J Cancer Res Clin Oncol; 2006 Dec;132(12):811-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DeltaNp63 protein expression in uterine cervical and endometrial cancers.
  • PURPOSE: To investigate the significance of p63 expression in uterine cervical and endometrial cancers.
  • MATERIALS AND METHODS: DeltaNp63 protein expression was studied in a variety of 127 cases of uterine cervical lesions (20 non-neoplastic cervices, 43 cervical intraepithelial neoplasia [CIN], 54 squamous cell carcinomas (SCCs), 40 adenocarcinomas, and 13 other histologic types) and 30 endometrioid type of endometrial adenocarcinomas by using immunohistochemistry.
  • One SCC cell line (ME-180) and one adenocarcinoma cell line (HeLa) were also included.
  • RESULTS: In uterine cervix, the expression of DeltaNp63 was increased with progression of CIN, and positive in all SCCs, transitional cell carcinomas, and adenoid basal carcinoma, but negative in all adenocarcinomas.
  • Adenosquamous cell carcinoma and mixed neuroendocrine and squamous cell carcinoma were positive in squamous component, but not in adenocarcinoma and neuroendocrine carcinoma components.
  • ME-180 cell line was positive, whereas HeLa cell line was negative.
  • CONCLUSIONS: Immunohistochemical staining for DeltaNp63 is a powerful marker for squamous differentiation and useful in exclusion of glandular and neuroendocrine differentiation in uterine cervical cancers, but not always in endometrial cancers.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. DNA-Binding Proteins / biosynthesis. Endometrial Neoplasms / metabolism. Trans-Activators / biosynthesis. Tumor Suppressor Proteins / biosynthesis. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Antigens, Differentiation / biosynthesis. Cell Line, Tumor. Cervix Uteri / cytology. Cervix Uteri / metabolism. Female. HeLa Cells. Humans. Immunohistochemistry. Transcription Factors

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16804722.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / DNA-Binding Proteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


27. Kobayashi Y, Wada Y, Ohara T, Okuda Y, Suzuki N, Hasegawa K, Kiguchi K, Ishizuka B: Enzymatic activities of uridine and thymidine phosphorylase in normal and cancerous uterine cervical tissues. Hum Cell; 2007 Nov;20(4):107-10
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enzymatic activities of uridine and thymidine phosphorylase in normal and cancerous uterine cervical tissues.
  • In this study, the preliminary analyses were conducted of enzymatic activities of uridine phosphorylase (UP) and thymidine phosphorylase (TP) in normal tissues and cancer tissues of the uterine cervix.
  • The study was performed on 27 patients of cervical cancer, treated first in our hospital.
  • Normal cervical tissues obtained from 15 patients undergoing hysterectomy for benign diseases were used as controls.
  • The supernatant of the homogenated cervical tissues and the stroma (5-FU and ribose-1-P or deoxyribose-1-P) were analyzed by high performance liquid chromatography, and then the UP and TP activities calculated.
  • Both UP and TP showed significantly greater activity in cancer tissues than in normal tissues (P < 0.0001).
  • In the TP activity of the cancer tissues, there was no significant difference among the histological types, while the TP activity tended to be significantly higher in the cases with lymph node metastasis.
  • These results showed that the TP-mediated route seemed important as the 5FU metabolic pathway in the uterine cervical tissues, and TP enzymatic activity might be associated with lymph node metastasis.
  • [MeSH-major] Adenocarcinoma / enzymology. Carcinoma, Adenosquamous / enzymology. Carcinoma, Squamous Cell / enzymology. Cervix Uteri / enzymology. Thymidine Phosphorylase / metabolism. Uridine Phosphorylase / metabolism. Uterine Cervical Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17949350.001).
  • [ISSN] 0914-7470
  • [Journal-full-title] Human cell
  • [ISO-abbreviation] Hum. Cell
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 2.4.2.3 / Uridine Phosphorylase; EC 2.4.2.4 / Thymidine Phosphorylase; U3P01618RT / Fluorouracil
  •  go-up   go-down


28. Lizano M, De la Cruz-Hernández E, Carrillo-García A, García-Carrancá A, Ponce de Leon-Rosales S, Dueñas-González A, Hernández-Hernández DM, Mohar A: Distribution of HPV16 and 18 intratypic variants in normal cytology, intraepithelial lesions, and cervical cancer in a Mexican population. Gynecol Oncol; 2006 Aug;102(2):230-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of HPV16 and 18 intratypic variants in normal cytology, intraepithelial lesions, and cervical cancer in a Mexican population.
  • These variants are associated with populations from different geographic regions, and show a differential distribution among the severity of the cervical lesion, most likely due to different pathogenic potential.
  • The objective of this study was to investigate the variant distribution of HPV16 and 18 in a Mexican population and its association with the severity of the cervical lesion and the histological lineage of cervical cancer.
  • METHODS: HPV types 16 and 18 detection was performed in 412 samples of preinvasive and invasive specimens from patients attending a Primary Health-Care Center, an Early Cervical Lesion Clinic, or a Cancer Center.
  • Distribution of HPV variants was correlated with the cytological findings and tumor cell types using contingency tables.
  • RESULTS: Among the 277 women included in this study without cancer, 63.5% (176 cases) had a normal cytology; from the remaining 101 women, 53.5% were LSIL (54 cases), and 46.5% HSIL (47 cases).
  • From a total of 135 invasive carcinomas, 78.5% were squamous (106 cases); 6.6% adenocarcinoma (9 cases); 9.6% adenosquamous (ADSC) (13 cases); and 5.1% were undifferentiated carcinoma (7 cases).
  • However, the isolate AA-c was exclusively found in cervical cancer.
  • In invasive cancer, this variant was found only in squamous tumors.
  • CONCLUSIONS: The differential distribution of HPV16 and 18 variants in cervical lesions we found further supports experimental data on the different pathogenic potential of HPV16 and 18 variants for cervical cancer development.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / virology. Human papillomavirus 16 / isolation & purification. Human papillomavirus 18 / isolation & purification. Papillomavirus Infections / virology. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Cervix Uteri / virology. Female. Humans. Mexico / epidemiology


29. Smith HO, Jiang CS, Weiss GR, Hallum AV 3rd, Liu PY, Robinson WR 3rd, Cheng PC, Scudder SA, Markman M, Alberts DS: Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: a Southwest Oncology Group study. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):298-305
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: a Southwest Oncology Group study.
  • The objective of this study was to determine objective response and overall survival (OS) and progression-free survival (PFS) following cisplatin plus tirapazamine treatment in eligible consenting patients with metastatic or recurrent squamous or adenosquamous carcinoma of the cervix.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy. Uterine Cervical Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445649.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 12213; United States / NCI NIH HHS / CA / CA 12644; United States / NCI NIH HHS / CA / CA 13612; United States / NCI NIH HHS / CA / CA 22433; United States / NCI NIH HHS / CA / CA 32102; United States / NCI NIH HHS / CA / CA 35090; United States / NCI NIH HHS / CA / CA 35178; United States / NCI NIH HHS / CA / CA 35192; United States / NCI NIH HHS / CA / CA 35262; United States / NCI NIH HHS / CA / CA 35431; United States / NCI NIH HHS / CA / CA 38926; United States / NCI NIH HHS / CA / CA 42777; United States / NCI NIH HHS / CA / CA 45450; United States / NCI NIH HHS / CA / CA 45461; United States / NCI NIH HHS / CA / CA 46136; United States / NCI NIH HHS / CA / CA 46441; United States / NCI NIH HHS / CA / CA 52654; United States / NCI NIH HHS / CA / CA 58861; United States / NCI NIH HHS / CA / CA 76132; United States / NCI NIH HHS / CA / CA 76448
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Triazines; 1UD32YR59G / tirapazamine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


30. Zhang Z, Borecki I, Nguyen L, Ma D, Smith K, Huettner PC, Mutch DG, Herzog TJ, Gibb RK, Powell MA, Grigsby PW, Massad LS, Hernandez E, Judson PL, Swisher EM, Crowder S, Li J, Gerhard DS, Rader JS: CD83 gene polymorphisms increase susceptibility to human invasive cervical cancer. Cancer Res; 2007 Dec 1;67(23):11202-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD83 gene polymorphisms increase susceptibility to human invasive cervical cancer.
  • We previously mapped a nonrandom frequent loss of heterozygosity (LOH) region in cervical cancers to 1 Mb of 6p23.
  • Here, we describe the identification of a novel cervical cancer susceptibility gene, CD83.
  • Investigation of CD83 uncovered three alternative transcripts in cervical tissue and cell lines, with variant 3 (lacking exons 3 and 4) being more frequent in cervical cancer than in normal cervical epithelium (P = 0.0181).
  • Genomic sequencing on 36 paired normal and cervical tumors revealed several somatic mutations and novel SNPs in the promoter, exons, and introns of CD83.
  • LOH was confirmed in >90% of cervical cancer specimens.
  • Immunofluorescence colocalized CD83 protein to the Golgi apparatus and cell membrane of cervical cancer cell lines.
  • None of seven nearby genes was differentially expressed in cervical cancer.
  • The importance of CD83 in epithelial versus dendritic cells needs to be determined, as does its role in promoting cervical cancer.
  • [MeSH-major] Antigens, CD / genetics. Genetic Predisposition to Disease. Immunoglobulins / genetics. Membrane Glycoproteins / genetics. Polymorphism, Single Nucleotide. Uterine Cervical Neoplasms / genetics. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenocarcinoma / virology. Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / virology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / virology. Cervical Intraepithelial Neoplasia / genetics. Cervical Intraepithelial Neoplasia / pathology. Cervical Intraepithelial Neoplasia / virology. Cervix Uteri / metabolism. Cervix Uteri / pathology. Chromosomes, Human, Pair 6 / genetics. Exons. Expressed Sequence Tags. Female. Fluorescent Antibody Technique. Gene Expression Regulation, Neoplastic. Genotype. Humans. Loss of Heterozygosity. Neoplasm Invasiveness / pathology. Papillomaviridae / genetics. Papillomavirus Infections / genetics. Papillomavirus Infections / pathology. Papillomavirus Infections / virology. Polymerase Chain Reaction. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18056445.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5R01CA094141; United States / NCI NIH HHS / CA / 5R01CA095713
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD83 antigen; 0 / Immunoglobulins; 0 / Membrane Glycoproteins
  •  go-up   go-down


31. Nijhuis ER, van der Zee AG, in 't Hout BA, Boomgaard JJ, de Hullu JA, Pras E, Hollema H, Aalders JG, Nijman HW, Willemse PH, Mourits MJ: Gynecologic examination and cervical biopsies after (chemo) radiation for cervical cancer to identify patients eligible for salvage surgery. Int J Radiat Oncol Biol Phys; 2006 Nov 1;66(3):699-705
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gynecologic examination and cervical biopsies after (chemo) radiation for cervical cancer to identify patients eligible for salvage surgery.
  • PURPOSE: The aim of this study was to evaluate efficacy of gynecologic examination under general anesthesia with cervical biopsies after (chemo) radiation for cervical cancer to identify patients with residual disease who may benefit from salvage surgery.
  • METHODS AND MATERIALS: In a retrospective cohort study data of all cervical cancer patients with the International Federation of Gynecology and Obstetrics (FIGO) Stage IB1 to IVA treated with (chemo) radiation between 1994 and 2001 were analyzed.
  • Cervical biopsy samples were taken from patients judged to be operable.
  • In case of residual cancer, salvage surgery was performed.
  • RESULTS: Between 1994 and 2001, 169 consecutive cervical cancer patients received primary (chemo) radiation, of whom 4 were lost to follow-up.
  • CONCLUSIONS: Gynecologic examination under anesthesia 8 to 10 weeks after (chemo) radiation with cervical biopsies allows identification of those cervical cancer patients who have residual local disease, of whom a small but significant proportion may be salvaged by surgery.
  • [MeSH-major] Cervix Uteri / pathology. Salvage Therapy. Uterine Cervical Neoplasms
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Anesthesia, General. Biopsy. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Combined Modality Therapy / methods. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm, Residual. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16904839.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. de Boer MA, Vet JN, Aziz MF, Cornain S, Purwoto G, van den Akker BE, Dijkman A, Peters AA, Fleuren GJ: Human papillomavirus type 18 and other risk factors for cervical cancer in Jakarta, Indonesia. Int J Gynecol Cancer; 2006 Sep-Oct;16(5):1809-14
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus type 18 and other risk factors for cervical cancer in Jakarta, Indonesia.
  • Infection with human papillomavirus (HPV) has now been established as a necessary cause of cervical cancer.
  • Indonesia is a country with a high cervical cancer incidence and with the world's highest prevalence of HPV 18 in cervical cancer.
  • A total of 74 cervical carcinoma cases and 209 control women, recruited from the gynecological outpatient clinic of the same hospital, were included.
  • All women were HPV typed by the line probe assay, and interviews were obtained regarding possible risk factors for cervical cancer.
  • In addition to HPV infection, young age at first intercourse, having a history of more than one sexual partner, and high parity were significant risk factors for cervical cancer.
  • We hypothesize that the high prevalence of HPV 18 in cervical cancer in Indonesia is caused by the high prevalence of HPV 18 in the Indonesian population.
  • [MeSH-major] Carcinoma, Adenosquamous / virology. Carcinoma, Squamous Cell / virology. Human papillomavirus 18. Papillomavirus Infections / epidemiology. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Adult. Case-Control Studies. Cervix Uteri / virology. Female. Human papillomavirus 16. Humans. Indonesia / epidemiology. Middle Aged. Prevalence. Risk Factors

  • Genetic Alliance. consumer health - Cervical cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009976.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Coleman DV, Poznansky JJ: Review of cervical smears from 76 women with invasive cervical cancer: cytological findings and medicolegal implications. Cytopathology; 2006 Jun;17(3):127-36
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of cervical smears from 76 women with invasive cervical cancer: cytological findings and medicolegal implications.
  • OBJECTIVE: To review cervical smears from 76 women which were taken prior to the diagnosis of invasive cervical cancer and to determine the appropriateness of the cytology reports issued on the smears.
  • METHODS: Cervical smears, clinical records, cervical smear history and cytology reports from 76 women with invasive cervical cancer were reviewed.
  • After microscopic review of the cervical smears, the cases were divided into two groups: Group 1 comprised 50 women who were found to have had at least one false-negative (F/N) smear report prior to the diagnosis of invasive cervical cancer.
  • RESULTS: A total of 209 cervical smears from the 50 women in group 1 were available for review (range 2-12 smears per woman); 100 of the 209 smears were considered to have been reported appropriately.
  • Forty women developed invasive squamous carcinoma and 10 developed invasive adenocarcinoma.
  • The stage at diagnosis ranged from 1A to stage 4.
  • Nineteen women were diagnosed with squamous cancer, two microinvasive cancer, one glassy cell, two adenocarcinomas, and one with adenosquamous carcinoma.
  • One women was found to have an embryonal rhabdomyosarcoma of the corpus uteri involving the cervix.
  • There was no evidence of failure of duty of care in terms of the standard of the cervical cytology reports issued or standard of clinical management in 17 of the 26 cases in group 2.
  • [MeSH-major] Malpractice. Pathology, Clinical / legislation & jurisprudence. Uterine Cervical Neoplasms / pathology. Vaginal Smears / methods


34. Chumworathayi B, Suprasert P, Charoenkwan K, Srisomboon J, Phongnarisorn C, Siriaree S, Cheewakriangkrai C, Tantipalakorn J, Kiatpeerakul C, Pantusart A: Weekly versus three-weekly cisplatin as an adjunct to radiation therapy in high-risk stage I-IIA cervical cancer after surgery: a randomized comparison of treatment compliance. J Med Assoc Thai; 2005 Nov;88(11):1483-92
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly versus three-weekly cisplatin as an adjunct to radiation therapy in high-risk stage I-IIA cervical cancer after surgery: a randomized comparison of treatment compliance.
  • OBJECTIVES: To compare weekly and three-weekly cisplatin as an adjunct to radiation therapy in high-risk early-stage cervical cancer after surgery with regard to treatment compliance.
  • MATERIAL AND METHOD: From June 1st, 2003 to February 29th, 2004, the authors performed a randomized trial of radiotherapy in combination with two concurrent chemotherapy regimens - weekly or three-weekly cisplatin--in patients with high-risk cervical cancer FIGO stage I-IIA after surgery.
  • Women with primary invasive squamous-cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix were enrolled.
  • CONCLUSION: Concurrent chemoradiation with weekly cisplatin regimen has more complete treatment rate and less delayed courses than that with three- weekly cisplatin among women with high-risk cervical cancer after surgery.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / administration & dosage. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Squamous Cell / drug therapy. Cisplatin / administration & dosage. Patient Compliance. Uterine Cervical Neoplasms / drug therapy


35. Lennerz JK, Perry A, Mills JC, Huettner PC, Pfeifer JD: Mucoepidermoid carcinoma of the cervix: another tumor with the t(11;19)-associated CRTC1-MAML2 gene fusion. Am J Surg Pathol; 2009 Jun;33(6):835-43
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoepidermoid carcinoma of the cervix: another tumor with the t(11;19)-associated CRTC1-MAML2 gene fusion.
  • Mucoepidermoid carcinoma (MEC) of the uterine cervix is a controversial entity.
  • By strict morphologic criteria, the tumor has features identical to those of salivary gland MEC and is characterized by nests composed of 3 cell types (epidermoid, intermediate, and mucin producing) in the absence of overt glandular differentiation.
  • Nonetheless, the entity is not recognized in the current World Health Organization classification of cervical tumors.
  • Given the morphologic similarity between MEC of the cervix and MEC of the salivary glands, we sought to determine if MEC of the cervix harbors the t(11;19)(q21;p13) characteristic of MEC of the major and minor salivary glands, a rearrangement that results in fusion of the cyclic adenosine 3',5' monophosphate coactivator CRTC1 to the Notch coactivator MAML2.
  • We identified 7 cervical tumors from our departmental files and performed reverse transcription-polymerase chain reaction and fluorescence in situ hybridization-based molecular analysis for rearrangements of CRTC1 and MAML2; 14 conventional cervical adenosquamous carcinomas were used as controls.
  • Analysis of the cervical MECs demonstrated a CRTC1-MAML2 fusion in 1 case, rearrangements of CRTC1 in 4 cases, and aberrations of MAML2 in 5 cases (rearrangements in 2 cases, amplification in 3 cases).
  • All MEC showed aberrations of at least 1 of the loci, whereas none of the cervical adenosquamous carcinomas harbored rearrangements or amplification of either locus.
  • Our results demonstrate that cervical tumors defined as MEC by strict morphologic criteria harbor genetic aberrations involving the genes characteristically rearranged in MEC of the salivary glands, and suggest that cervical MEC is an entity distinct from conventional cervical adenosquamous carcinoma.
  • The development of drug therapy targeted to the genes rearranged in MEC underscores the importance of correct classification of cervical MEC because the diagnosis may hold therapeutic implications different from other cervical malignancies.

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19092631.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK079798-01A2; United States / NIDDK NIH HHS / DK / K08 DK066062; United States / NIDDK NIH HHS / DK / R01 DK079798; United States / NIDDK NIH HHS / DK / R01 DK079798-01A2; United States / NIDDK NIH HHS / DK / K08 DK066062-05; United States / NIDDK NIH HHS / DK / DK066062-05
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CRTC1 protein, human; 0 / DNA-Binding Proteins; 0 / MAML2 protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / Transcription Factors
  •  go-up   go-down


37. Fumerton R, Afifi T, Martinka M, de Gannes G: Cutaneous metastases of cervical adenosquamous carcinoma. J Am Acad Dermatol; 2010 Aug;63(2):e48-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous metastases of cervical adenosquamous carcinoma.
  • [MeSH-major] Carcinoma, Adenosquamous / secondary. Cervical Intraepithelial Neoplasia / pathology. Skin Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20633787.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down






Advertisement